MX356204B - Regimen de dosificacion de toxina botulinica para la profilaxis de la migraña cronica. - Google Patents
Regimen de dosificacion de toxina botulinica para la profilaxis de la migraña cronica.Info
- Publication number
- MX356204B MX356204B MX2015008642A MX2015008642A MX356204B MX 356204 B MX356204 B MX 356204B MX 2015008642 A MX2015008642 A MX 2015008642A MX 2015008642 A MX2015008642 A MX 2015008642A MX 356204 B MX356204 B MX 356204B
- Authority
- MX
- Mexico
- Prior art keywords
- botulinum toxin
- fixed
- site
- dose
- injection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a los trastornos tales como cefaleas pueden tratarse mediante la administración de una toxina botulínica a un paciente que sufre de la misma, tal como una cefalea migrañosa. Una dosis fija en sitio fijo combinada y un paradigma de dosificación opcional variable de seguimiento del dolor y sitio de inyección se describe para optimizar la efectividad clínica de la administración de la toxina botulínica para pacientes que sufren cefalea, particularmente migraña crónica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31923010P | 2010-03-30 | 2010-03-30 | |
US32066710P | 2010-04-02 | 2010-04-02 | |
PCT/US2011/030370 WO2011123456A1 (en) | 2010-03-30 | 2011-03-29 | Botulinum toxin dosage regimen for chronic migraine prophylaxis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX356204B true MX356204B (es) | 2018-05-18 |
Family
ID=44169214
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015008642A MX356204B (es) | 2010-03-30 | 2011-03-29 | Regimen de dosificacion de toxina botulinica para la profilaxis de la migraña cronica. |
MX2012011227A MX2012011227A (es) | 2010-03-30 | 2011-03-29 | Regimen de dosificacion de toxina botulinica para la profilaxis de la migraña cronica. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012011227A MX2012011227A (es) | 2010-03-30 | 2011-03-29 | Regimen de dosificacion de toxina botulinica para la profilaxis de la migraña cronica. |
Country Status (23)
Country | Link |
---|---|
US (9) | US20100266638A1 (es) |
EP (4) | EP2552475B1 (es) |
JP (4) | JP5700874B2 (es) |
KR (2) | KR20130052731A (es) |
CN (1) | CN102917728A (es) |
AU (1) | AU2011211375B2 (es) |
BR (1) | BR112012024920B1 (es) |
CA (2) | CA2794782C (es) |
CY (1) | CY1117910T1 (es) |
DK (1) | DK2552475T3 (es) |
ES (1) | ES2587437T3 (es) |
HK (1) | HK1179875A1 (es) |
HU (1) | HUE030094T2 (es) |
IL (2) | IL222192A (es) |
MX (2) | MX356204B (es) |
MY (1) | MY156827A (es) |
NZ (2) | NZ602983A (es) |
PL (1) | PL2552475T3 (es) |
PT (1) | PT2552475T (es) |
RU (1) | RU2549981C9 (es) |
SG (1) | SG184339A1 (es) |
SI (1) | SI2552475T1 (es) |
WO (1) | WO2011123456A1 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US7758872B1 (en) | 2003-02-07 | 2010-07-20 | Eric Finzi | Method of treating depression |
US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US9687186B2 (en) | 2005-07-21 | 2017-06-27 | Steadymed Ltd. | Drug delivery device |
IL175460A (en) | 2006-05-07 | 2011-05-31 | Doron Aurbach | Drug delivery device |
US9061025B2 (en) * | 2006-08-31 | 2015-06-23 | Allergan, Inc. | Methods for selecting headache patients responsive to botulinum toxin therapy |
SG185338A1 (en) * | 2007-10-23 | 2012-11-29 | Allergan Inc | Methods of treating urogenital-neurological disorders using modified clostridial toxins |
US8617571B2 (en) * | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
SG10202100698QA (en) | 2008-12-31 | 2021-02-25 | Revance Therapeutics Inc | Injectable Botulinum Toxin Formulations |
US9340587B2 (en) | 2009-06-25 | 2016-05-17 | Revance Therapeutics, Inc. | Albumin-free botulinum toxin formulations |
WO2011041483A2 (en) * | 2009-09-30 | 2011-04-07 | Toxcure, Inc. | Use of botulinum neurotoxin to treat substance addictions |
US8940308B2 (en) | 2010-03-30 | 2015-01-27 | Allergan, Inc. | Methods for treating depression |
EP2621558B1 (en) | 2010-09-27 | 2018-11-21 | Steadymed Ltd. | Size-efficient drug-delivery device |
US20120251574A1 (en) * | 2011-03-28 | 2012-10-04 | Allergan, Inc. | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions |
US10111938B2 (en) | 2011-03-30 | 2018-10-30 | Allergan, Inc. | Injection paradigm for administration of botulinum toxins |
US9764009B2 (en) | 2011-06-13 | 2017-09-19 | Allergan, Inc. | Treatment of psychological trauma |
RU2578475C2 (ru) | 2011-07-14 | 2016-03-27 | Аллерган, Инк. | Способы лечения недержания, связанного с половой активностью |
US10071209B2 (en) | 2012-03-15 | 2018-09-11 | Steadymed Ltd. | Enhanced infusion-site pain-reduction for drug-delivery devices |
WO2013140395A1 (en) | 2012-03-19 | 2013-09-26 | Steadymed Ltd. | Fluid-connection mechanism for patch-pumps |
ES2424294B1 (es) | 2012-03-22 | 2014-07-21 | Lipotec, S.A. | Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas |
EP2649983A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (II) |
EP2649985A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (III) |
BR112014025396B1 (pt) | 2012-04-13 | 2020-03-17 | Lubrizol Advanced Materials, Inc. | Composto, composição cosmética ou farmacêutica, e, uso de um composto |
EP2649984A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis |
WO2014078724A1 (en) | 2012-11-16 | 2014-05-22 | Finzi Eric | Treatment of post-traumatic stress disorder using botulinum toxin a |
EP2976060B1 (en) | 2013-03-22 | 2016-10-26 | Lipotec, S.A. | Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails |
WO2015039244A1 (en) * | 2013-09-20 | 2015-03-26 | Mddt Inc. | Diagnosing and treating movement disorders |
US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
RU2670135C2 (ru) * | 2014-05-29 | 2018-10-18 | Проуселл Терапьютикс Инк. | Новый проникающий в клетки пептид, его конъюгат с ботулотоксином и их применение |
EP3154635A1 (en) * | 2014-06-13 | 2017-04-19 | Merz Pharma GmbH & Co. KGaA | Novel uses of recombinant clostridial neurotoxins with decreased duration of effect |
JP2018515271A (ja) * | 2015-05-15 | 2018-06-14 | カリリオン・クリニックCarilion Clinic | 過活動膀胱を処置するための注射器及びこれら注射器を使用する方法 |
US10463847B2 (en) | 2015-06-11 | 2019-11-05 | Steadymed Ltd. | Infusion set |
CN109069609A (zh) * | 2015-12-11 | 2018-12-21 | 雷文斯治疗公司 | 使用神经递质的用于原发性情绪和情感障碍的肉毒杆菌毒素 |
JP2019526611A (ja) | 2016-09-13 | 2019-09-19 | アラーガン、インコーポレイテッドAllergan,Incorporated | 非タンパク質クロストリジウム毒素組成物 |
US20200023044A1 (en) * | 2017-03-22 | 2020-01-23 | Bonti, Inc. | Botulinum neurotoxins for treating traumatic injuries |
IT201800001119A1 (it) * | 2018-01-16 | 2019-07-16 | Francesco Giuseppe Bono | Metodo regionalizzato e focalizzato di somministrazione di tossina botulinica mediante iniezione intradermica- subdermica-sottocutanea per il trattamento dell’emicrania cronica intrattabile e della cefalea |
EP3817766A2 (en) * | 2018-07-05 | 2021-05-12 | Allergan Pharmaceuticals International Limited | Combination therapy with cgrp antagonists and clostridial derivatives |
US11752201B2 (en) | 2019-01-07 | 2023-09-12 | Babak Azizzadeh | Treatment of stress disorders, including post-traumatic stress disorder, using acetylcholine release inhibiting neurotoxic proteins to reduce stress levels |
AU2020340428A1 (en) | 2019-08-30 | 2022-03-03 | AEON Biopharma, Inc. | Neurotoxin compositions for use in treating headache |
BR112022018670A2 (pt) * | 2020-03-18 | 2022-11-01 | Revance Therapeutics Inc | Métodos de toxina botulínica injetável para tratar cefaleia |
RU2763476C1 (ru) * | 2021-01-13 | 2021-12-29 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) | Способ лечения мигрени |
WO2023075060A1 (ko) * | 2021-10-25 | 2023-05-04 | 비피메드(주) | 보툴리눔 유래 펩타이드를 포함하는 통증개선용 조성물 |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA962933A (en) | 1969-12-05 | 1975-02-18 | Yutaka Hori | Metal foil-plastic laminated film and method of producing the same |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US6974578B1 (en) * | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
CA2312047A1 (en) * | 1994-05-09 | 1995-11-16 | William J. Binder | Method for reduction of headache pain |
US5670484A (en) * | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
GB9510223D0 (en) * | 1995-05-20 | 1995-07-19 | Pfizer Ltd | Therapeutic agent |
US6063768A (en) * | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
EP1128844B1 (en) * | 1998-10-27 | 2006-01-04 | Mayo Foundation For Medical Education And Research | Botulinum toxins for enhancing wound healing |
US6358917B1 (en) * | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
US6139845A (en) * | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
US20030118598A1 (en) | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
DK1253932T3 (da) | 2000-02-08 | 2005-06-27 | Allergan Inc | Lægemidler med botulinustoxin |
US20010036943A1 (en) * | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6299893B1 (en) * | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
US6423319B1 (en) * | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
US20020086036A1 (en) * | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
AU2002355730B2 (en) | 2001-07-27 | 2007-09-13 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Botulinum toxin in the treatment or prevention of acne |
US6623742B2 (en) * | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
DE10150415A1 (de) * | 2001-10-11 | 2003-05-15 | Andres O Ceballos-Baumann | Arzneimittel zur Prophylaxe und Therapie von Depressionen |
US7077610B2 (en) | 2002-02-07 | 2006-07-18 | Buern Usa, L.L.C. | Toggle bolt device |
WO2003073994A2 (en) * | 2002-03-01 | 2003-09-12 | Elan Pharmaceuticals, Inc. | Methods of treating nerve entrapment syndromes |
US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
US20040266776A1 (en) * | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
WO2004035011A2 (en) | 2002-10-15 | 2004-04-29 | Allergan, Inc. | Botulinum toxin dental therapies and procedures |
US7758872B1 (en) | 2003-02-07 | 2010-07-20 | Eric Finzi | Method of treating depression |
US8691769B2 (en) | 2003-03-06 | 2014-04-08 | Botulinum Toxin Research Associates, Inc. | Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections |
US7393537B2 (en) * | 2003-04-25 | 2008-07-01 | Allergan, Inc. | Botulinum toxin for treatment of obsessive compulsive finger biting disorder |
US6838434B2 (en) * | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US8617572B2 (en) | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8609113B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8609112B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
US7270287B2 (en) * | 2004-01-06 | 2007-09-18 | Allergan, Inc. | Botulinum toxin treatment for kinesia |
US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
US7299081B2 (en) * | 2004-06-15 | 2007-11-20 | Abbott Laboratories | Analyte test device |
KR100852822B1 (ko) | 2004-07-26 | 2008-08-18 | 메르츠 파마 게엠베하 운트 코. 카가아 | 보툴리눔 신경독소를 포함하는 치료 조성물 |
US7897147B2 (en) | 2004-10-20 | 2011-03-01 | Allergan, Inc. | Treatment of premenstrual disorders |
CA2588758C (en) * | 2004-11-22 | 2017-01-03 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
WO2006078588A2 (en) * | 2005-01-18 | 2006-07-27 | Allergan, Inc. | Improved methods for treating headache |
US7655244B2 (en) | 2005-02-01 | 2010-02-02 | Allergan, Inc. | Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions |
US7749515B2 (en) | 2005-02-01 | 2010-07-06 | Allergan, Inc. | Targeted delivery of botulinum toxin to the sphenopalatine ganglion |
US8926991B2 (en) * | 2005-06-14 | 2015-01-06 | Botulinum Toxin Research Associates, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
US20150258183A1 (en) * | 2006-06-07 | 2015-09-17 | Botulinum Toxin Research Associates, Inc. | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect |
US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
JP5276982B2 (ja) | 2005-08-26 | 2013-08-28 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | オキシトシンの投与による頭痛の処置のための方法 |
US7824694B2 (en) | 2006-01-12 | 2010-11-02 | Allergan, Inc. | Methods for enhancing therapeutic effects of a neurotoxin |
US20080021437A1 (en) | 2006-04-27 | 2008-01-24 | Boyd James P | Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A |
GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
US9061025B2 (en) * | 2006-08-31 | 2015-06-23 | Allergan, Inc. | Methods for selecting headache patients responsive to botulinum toxin therapy |
RU2007104969A (ru) * | 2007-02-09 | 2008-08-20 | Маргарита Алексеевна Морозова (RU) | Способ лечения мигрени и применение алимемазина тартрата для лечения мигрени |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
US8617571B2 (en) * | 2008-04-03 | 2013-12-31 | Allergan, Inc. | Suture line administration technique using botulinum toxin |
EP2253343A1 (en) * | 2009-05-19 | 2010-11-24 | Fresenius Medical Care Deutschland GmbH | Safety insert for extra-corporeal circuits |
EP2477175B1 (en) | 2009-09-08 | 2015-11-04 | Joled Inc. | Display panel device and control method thereof |
US20120329764A1 (en) | 2010-01-08 | 2012-12-27 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment of migraine headaches |
US8940308B2 (en) | 2010-03-30 | 2015-01-27 | Allergan, Inc. | Methods for treating depression |
US20130189354A1 (en) * | 2010-10-07 | 2013-07-25 | Trinity Laboratories, Inc., | Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy |
EP2667859A2 (en) * | 2011-01-24 | 2013-12-04 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
US10111938B2 (en) * | 2011-03-30 | 2018-10-30 | Allergan, Inc. | Injection paradigm for administration of botulinum toxins |
RU2578475C2 (ru) | 2011-07-14 | 2016-03-27 | Аллерган, Инк. | Способы лечения недержания, связанного с половой активностью |
US8491917B1 (en) | 2012-03-12 | 2013-07-23 | William J. Bender | Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head |
KR102042398B1 (ko) | 2012-04-03 | 2019-11-27 | 바스프 에스이 | 식물성 레시틴을 포함하는 모발 화장용 조성물 |
US9005628B2 (en) * | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
WO2014117148A1 (en) * | 2013-01-28 | 2014-07-31 | New York University | Treatment methods using atoxic neurotoxin derivatives |
CN104981690B (zh) | 2013-02-06 | 2018-02-02 | 安捷伦科技有限公司 | 流体连接装置、组件及相关方法 |
US20140294923A1 (en) | 2013-02-20 | 2014-10-02 | Questcor Pharmaceuticals, Inc. | Acth for treatment of migraine headache |
WO2014150899A1 (en) | 2013-03-15 | 2014-09-25 | Chapin Matthew J | Topical ophthalmic formulations for treating migraine |
US10933230B2 (en) * | 2013-05-06 | 2021-03-02 | Medtronic, Inc. | Systems and methods for implanting a medical electrical lead |
US9216210B2 (en) * | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
KR20220130822A (ko) * | 2014-03-21 | 2022-09-27 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법 |
JP6738739B2 (ja) | 2014-04-30 | 2020-08-12 | アラーガン、インコーポレイテッドAllergan,Incorporated | 膀胱内滴下注入用生物製剤 |
EP3191118A1 (en) | 2014-09-12 | 2017-07-19 | Allergan, Inc. | Methods for treating osteoarthritis pain |
JOP20200116A1 (ar) * | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
US11039506B2 (en) | 2017-11-30 | 2021-06-15 | International Business Machines Corporation | Stove control safety mechanism |
EP3817766A2 (en) * | 2018-07-05 | 2021-05-12 | Allergan Pharmaceuticals International Limited | Combination therapy with cgrp antagonists and clostridial derivatives |
-
2010
- 2010-06-03 US US12/793,603 patent/US20100266638A1/en not_active Abandoned
-
2011
- 2011-03-29 PT PT117135772T patent/PT2552475T/pt unknown
- 2011-03-29 NZ NZ602983A patent/NZ602983A/en unknown
- 2011-03-29 EP EP11713577.2A patent/EP2552475B1/en active Active
- 2011-03-29 MX MX2015008642A patent/MX356204B/es unknown
- 2011-03-29 CN CN2011800266584A patent/CN102917728A/zh active Pending
- 2011-03-29 EP EP17189376.1A patent/EP3311831A1/en not_active Withdrawn
- 2011-03-29 JP JP2013502757A patent/JP5700874B2/ja active Active
- 2011-03-29 DK DK11713577.2T patent/DK2552475T3/en active
- 2011-03-29 RU RU2012145786/15A patent/RU2549981C9/ru active
- 2011-03-29 EP EP22184142.2A patent/EP4140499A1/en active Pending
- 2011-03-29 KR KR1020127028238A patent/KR20130052731A/ko not_active Application Discontinuation
- 2011-03-29 KR KR1020157019453A patent/KR101786040B1/ko active IP Right Grant
- 2011-03-29 SG SG2012072328A patent/SG184339A1/en unknown
- 2011-03-29 EP EP14156327.0A patent/EP2735313A1/en not_active Ceased
- 2011-03-29 SI SI201130929A patent/SI2552475T1/sl unknown
- 2011-03-29 CA CA2794782A patent/CA2794782C/en active Active
- 2011-03-29 NZ NZ700623A patent/NZ700623A/en unknown
- 2011-03-29 HU HUE11713577A patent/HUE030094T2/en unknown
- 2011-03-29 BR BR112012024920-7A patent/BR112012024920B1/pt active IP Right Grant
- 2011-03-29 WO PCT/US2011/030370 patent/WO2011123456A1/en active Application Filing
- 2011-03-29 AU AU2011211375A patent/AU2011211375B2/en active Active
- 2011-03-29 ES ES11713577.2T patent/ES2587437T3/es active Active
- 2011-03-29 CA CA3019983A patent/CA3019983A1/en active Pending
- 2011-03-29 PL PL11713577.2T patent/PL2552475T3/pl unknown
- 2011-03-29 MX MX2012011227A patent/MX2012011227A/es active IP Right Grant
- 2011-03-29 MY MYPI2012004288A patent/MY156827A/en unknown
- 2011-03-30 US US13/075,485 patent/US8501195B2/en active Active
-
2012
- 2012-09-27 IL IL222192A patent/IL222192A/en active IP Right Grant
-
2013
- 2013-04-16 US US13/863,487 patent/US8936790B2/en active Active
- 2013-04-16 US US13/863,512 patent/US8968747B2/en active Active
- 2013-04-16 US US13/863,522 patent/US9279001B2/en active Active
- 2013-06-20 HK HK13107199.9A patent/HK1179875A1/zh unknown
-
2014
- 2014-12-16 JP JP2014254293A patent/JP5977811B2/ja active Active
-
2016
- 2016-02-16 IL IL244154A patent/IL244154A0/en unknown
- 2016-03-01 US US15/057,866 patent/US9764011B2/en active Active
- 2016-05-12 JP JP2016096143A patent/JP2016164189A/ja active Pending
- 2016-08-17 CY CY20161100813T patent/CY1117910T1/el unknown
-
2017
- 2017-09-18 US US15/707,452 patent/US10406213B2/en active Active
-
2018
- 2018-03-13 JP JP2018045676A patent/JP2018090633A/ja active Pending
-
2019
- 2019-09-09 US US16/564,294 patent/US11033610B2/en active Active
-
2021
- 2021-06-14 US US17/347,317 patent/US11819541B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY156827A (en) | Botulinum toxin dosage regimen for chronic migraine prophylaxis | |
JP2013523753A5 (es) | ||
UY30450A1 (es) | Aplicacinn de alta frecuencia de terapia con toxina botulenica | |
NZ603717A (en) | Suture line administration technique using botulinum toxins | |
BR112013023774A2 (pt) | inibidores de glicosilceramida sintase | |
GB201318761D0 (en) | Compounds for the treatment of neuropsychiatric disorders | |
MX2009008228A (es) | N-adamantil benzamidas como inhibidores de la dehidrogenasa 11-beta-hidroxiesteroide. | |
MX2018002067A (es) | Manejo con tetraciclina de dermatosis asociada con inhibidor de egfr. | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
EA201200686A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера | |
MX337511B (es) | Medicamentos y metodos para tratar cefaleas. | |
WO2007111993A3 (en) | Polyamine analogs as therapeutic agents for skin diseases | |
JP2015509961A5 (es) | ||
WO2007087154A3 (en) | Methods for enhancing therapeutic effects of a neurotoxin | |
CR20140063A (es) | 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-onas sustituidas | |
BR112012009432A2 (pt) | anticorpo anti-hsv | |
PH12016500136A1 (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
UY33219A (es) | Cetoenoles cíclicos para terapias | |
RU2013132566A (ru) | Терапевтическое средство от грыжи межпозвоночного диска | |
MX358613B (es) | Tratamiento de dolor de cabeza por migraña con neurotoxina presinaptica. | |
MY196026A (en) | Stem Cell Conditioned Media for Clinical and Cosmetic Applications | |
MD20160066A2 (ro) | Modulatoare alosterice pozitive ale receptorului nicotinic acetilcolinic | |
NZ594807A (en) | Pharmaceutical composition comprising racemic aminopterin | |
WO2006078588A3 (en) | Improved methods for treating headache | |
Wang et al. | Electroacupuncture Alleviates Pain by Suppressing P2Y12R-Dependent Microglial Activation in Monoarthritic Rats |